Welcome to our dedicated page for CME GROUP SEC filings (Ticker: CME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CME GROUP's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CME GROUP's regulatory disclosures and financial reporting.
Michael G. Dennis, Global Head of Fixed Income at CME Group (CME), reported changes to his beneficial ownership in the company. On 09/15/2025 he acquired 2,608 Class A common shares at $258.83 each, bringing his direct holdings to 8,927.3766 shares. On 09/16/2025 he disposed of 289 shares at $259.83, leaving 8,638.3766 direct shares. The filing notes that the shares were surrendered to the company to satisfy tax withholding obligations upon the vesting of restricted stock on 09/16/2025. An additional 40.81 shares are held indirectly by his spouse.
Timothy Francis McCourt, Senior Managing Director, Global Head Equity & FX at CME Group Inc. (CME), reported changes in his beneficial ownership via a Form 4. On September 15, 2025 he surrendered 754 Class A shares to satisfy tax-withholding associated with restricted stock vesting and simultaneously acquired 2,752 Class A shares at $258.83 per share, bringing his direct holdings to 9,887 shares. On September 16, 2025 he surrendered an additional 379 shares at $259.83 per share for tax-withholding, leaving 9,508 shares beneficially owned after the transactions. The Form 4 was signed on behalf of Mr. McCourt on September 17, 2025.
Form 4 disclosure for Derek Sammann, Senior Managing Director, Global Head of Commodities Markets at CME Group (CME). The filing reports share surrender and vesting activity on September 15-16, 2025. Mr. Sammann surrendered 1,099 and 379 Class A shares to satisfy tax withholding obligations upon restricted stock vesting on those dates. The filing lists direct beneficial ownership amounts of 8,318; 11,362; and 10,983 Class A shares after respective transactions, and shows indirect holdings of 14,614 shares held by a trust and 8,336 shares held by his spouse. The form was signed on 09/17/2025.
Terrence A. Duffy, Chairman and CEO and a director of CME Group Inc. (CME), reported a purchase of 23,180 shares of Class A Common Stock on 09/15/2025 at a reported price of $258.83 per share. After the transaction he beneficially owns 90,804 shares. The Form 4 was signed on behalf of the reporting person by Margaret Austin Wright on 09/17/2025. No derivative transactions were reported.
Hilda Harris Piell, Sr. MD & Chief HR Officer at CME Group (CME), reported insider transactions on Form 4 showing share surrenders to cover tax withholding upon restricted stock vesting. On 09/15/2025 she disposed of 953 Class A shares at $258.83 each, reducing her holdings to 28,108 shares, and on the same date acquired 2,608 shares at $258.83, raising holdings to 30,716 shares. On 09/16/2025 she disposed of 325 shares at $259.83, leaving 30,391 shares beneficially owned after the reported transactions. The filing states the disposals were share surrenders to satisfy tax-withholding obligations tied to restricted stock vesting; the form was signed on 09/17/2025.
CME Group Inc. filed a Form 144 notifying of a proposed sale of 376 shares of common stock through Morgan Stanley Smith Barney LLC, for an aggregate market value of $97,368.96. The shares were acquired as restricted stock from the issuer on 09/15/2025 and the proposed sale date is 09/16/2025 on NASDAQ. The filing shows 360,377,042 shares outstanding, and the filer states they are unaware of any undisclosed material adverse information. No sales by the filer in the past three months are reported.
CME Group Inc. reported that Jack Tobin, its Managing Director and Chief Accounting Officer, has decided to retire from the company. He informed the company of his decision on September 9, 2025 and will continue serving as Chief Accounting Officer until October 30, 2026, providing more than a year for transition.
Mr. Tobin has held the Chief Accounting Officer role since 2015 and has been with CME Group for over 23 years. The company states that his retirement is voluntary and is not due to any disagreements regarding its accounting, operations, policies or practices. CME Group plans to begin a search for his successor, and Mr. Tobin will work with that person to support a smooth handover of responsibilities.
Sunil K. Cutinho, Chief Information Officer of CME Group Inc. (CME) reported two stock sale transactions on 08/26/2025. He sold 5,930 shares of CME Class A common stock at a weighted average price of $272.10 (prices ranged $271.69–$272.58) and sold 5,966 shares at a weighted average price of $270.85 (prices ranged $270.32–$271.21). The Form 4 shows the amount of Class A shares beneficially owned following the reported transactions as 23,406 shares on the first line and 17,440 shares on the second line. The filing was signed by an authorized representative for Mr. Cutinho and includes explanatory notes about aggregated sale prices.
Form 144 notice for CME Group, Inc. (CME) shows a proposed sale of 11,896 common shares valued at approximately $3,229,452.32, to be executed through Morgan Stanley Smith Barney on NASDAQ on 08/26/2025. The filer acquired the shares as performance shares (2,283 shares, acquired 03/15/2025) and restricted stock (9,613 shares, acquired 09/15/2020). No securities were reported sold in the past three months. The filing includes the standard representation that the seller is unaware of undisclosed material adverse information about the issuer.
CME Group Inc. (CME) Form 144 notice reports a proposed sale of 32,468 shares of Common stock through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $200,054.83 and approximate sale date of 08/18/2025. The shares were acquired as restricted stock from the issuer on 05/02/2024 and were fully paid on that date. The filing lists 360,377,042 shares outstanding. Certain fields such as the identity or relationship of the selling person and the filing contact details are not populated in the provided text. The filer represents they are not aware of undisclosed material adverse information and affirms the signature and certification language required by Form 144.